Bioisosteric phentolamine analogs as potent alpha-adrenergic antagonists.
The synthesis and biological evaluation of a new series of bioisosteric phentolamine analogs are described. Replacement of the carbon next to the imidazoline ring of phentolamine with a nitrogen atom provides compounds (2, 3) that are about 1.6 times and 4.1 times more potent functionally than phentolamine on rat alpha1-adrenergic receptors, respectively. In receptor binding assays, the affinities of phentolamine and its bioisosteric analogs were determined on the human embryonic kidney (HEK) and Chinese Hamster ovary (CHO) cell lines expressing the human alpha1- and alpha2-AR subtypes, respectively. Analogs 2 and 3, both, displayed higher binding affinities at the alpha2- versus the alpha1-ARs, affinities being the least at the alpha1B-AR. Binding affinities of the methoxy ether analog 2 were greater than those of the phenolic analog 3 at all six alpha-AR subtypes. One of the nitrogen atoms in the imidazoline ring of phentolamine was replaced with an oxygen atom to give compounds 4 and 5, resulting in a 2-substituted oxazoline ring. The low functional antagonist activity on rat aorta, and binding potencies of these two compounds on human alpha1A- and alpha2A-AR subtypes indicate that a basic functional group is important for optimum binding to the alpha1- and alpha2A-adrenergic receptors.
Hong
Seoung-Soo
SS
Department of Manufacturing Pharmacy, College of Pharmacy, Chungbuk National University, Cheongju, Chungbuk 360-763, Republic of Korea. shong@gtxinc.com
Bavadekar
Supriya A
SA
Lee
Sang-Il
SI
Patil
Popat N
PN
Lalchandani
S G
SG
Feller
Dennis R
DR
Miller
Duane D
DD
D000317:Adrenergic alpha-Antagonists / Q000138:chemical synthesis* / Q000494:pharmacology; D000818:Animals; D001011:Aorta; D002460:Cell Line; D006801:Humans; D010646:Phentolamine / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology; D051381:Rats; D018340:Receptors, Adrenergic, alpha-1 / Q000187:drug effects; D018341:Receptors, Adrenergic, alpha-2 / Q000187:drug effects; D013329:Structure-Activity Relationship; D014661:Vasoconstriction / Q000187:drug effects
C547713:ADRA1A protein, human; C547768:ADRA2A protein, human; C547715:Adra1a protein, rat; C547770:Adra2a protein, rat; D000317:Adrenergic alpha-Antagonists; D018340:Receptors, Adrenergic, alpha-1; D018341:Receptors, Adrenergic, alpha-2; D010646:Phentolamine